Mill Creek Capital Advisors’s Context Therapeutics CNTX Stock Holding History

Mill Creek Capital Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$274K	Hold	104,631	–	–	0.01%	216
2025 Q4	$154K	Hold	104,631	–	–	﹤0.01%	248
2025 Q3	$101K	Hold	104,631	–	–	﹤0.01%	270
2025 Q2	$68.6K	Buy	+104,631	New	+$75.2K	﹤0.01%	262
2025 Q1	–	Sell	-104,631	Closed	-$110K	–	252
2024 Q4	$110K	Hold	104,631	–	–	﹤0.01%	258
2024 Q3	$205K	Hold	104,631	–	–	﹤0.01%	239
2024 Q2	$210K	Hold	104,631	–	–	0.01%	244
2024 Q1	$144K	Hold	104,631	–	–	﹤0.01%	236
2023 Q4	$118K	Hold	104,631	–	–	﹤0.01%	236
2023 Q3	$158K	Hold	104,631	–	–	0.01%	218
2023 Q2	$167K	Hold	104,631	–	–	0.01%	230
2023 Q1	$58.8K	Hold	104,631	–	–	﹤0.01%	245
2022 Q4	$68.2K	Buy	+104,631	New	+$113K	﹤0.01%	225

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mill Creek Capital Advisors's CNTX Position: Q1 2026 in Review

Mill Creek Capital Advisors held its Context Therapeutics (CNTX) position steady in Q1 2026 at 104,631 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #216.

Mill Creek Capital Advisors first reported a position in CNTX in Q4 2022 and has held it in 13 quarters since. 60 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Mill Creek Capital Advisors held 104,631 shares of Context Therapeutics worth $274K as of Q1 2026.
Mill Creek Capital Advisors left its Context Therapeutics share count unchanged in Q1 2026.
Context Therapeutics made up 0.01% of Mill Creek Capital Advisors's portfolio in Q1 2026, its #216 holding.
Mill Creek Capital Advisors first reported a position in Context Therapeutics in Q4 2022 and has held it in 13 quarters since.
60 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Mill Creek Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.